1 domain / 2 areas / 1 specialization
re.Mind
Data updated
re.Mind Capital is a venture capital fund focused on mental health, brain health, and human flourishing, with a public website that lists its office in London and a Maltese company footer. Its site also describes it as a leading early-stage investor, and its legal pages identify re.Mind Capital Limited with an address in Sliema, Malta.
In the psychedelic ecosystem, re.Mind matters because its public stories and investment context show activity across brain-computer interfaces and psychedelic-related therapeutics, including a featured story about Delix and a story page highlighting Small Pharma. Public references also describe the fund as part of Christian Angermayer’s Apeiron ecosystem and as an investor in psychedelic medicine alongside other neurotechnology and mental health themes.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.
re.Mind Capital appears to be a specialist venture investor in mental and neurological health, with a portfolio orientation that spans neurotechnology, brain health, and psychedelic-adjacent therapeutics. Public materials place it in the Apeiron ecosystem and show ongoing coverage of companies such as Precision Neuroscience, Blackrock Neurotech, Delix, and Small Pharma, suggesting an investment thesis centered on early-stage innovation in mind-related health platforms rather than a narrow single-asset strategy.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Explicit Psychedelic Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Quick Facts
- HQ
- Sliema, Malta, Malta
- Website
- Visit